Proposed FDA Generic Drug Labeling Policy Questioned

被引：0

|

作者：

不详

机构：

来源：

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2014年 / 311卷 / 10期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

收藏

页码：1005 / 1005

页数：1

相关论文

共 50 条

[31] Safety of FDA approval speed questioned
不详
JOURNAL OF NUCLEAR MEDICINE, 2008, 49 (05) : 29N - 30N
[32] Sources of drug information: FDA-approved labeling and other official FDA sources
Lindstrom, Jill A.
DERMATOLOGIC THERAPY, 2009, 22 (03) : 246 - 256
[33] Repositioning Generics: The Comparative Value of Liability in FDA's Proposed Rule on Labeling
Falcone, Nicholas
AMERICAN JOURNAL OF LAW & MEDICINE, 2015, 41 (2-3) : 483 - 504
[34] PROTROPIN STATUS QUESTIONED BY FDA DECISION
EZZELL, C
NATURE, 1987, 326 (6110) : 231 - 231
[35] FOOD AND DRUG ADMINISTRATIONS PROPOSED LABELING RULES FOR PROTEIN
不详
JOURNAL OF THE AMERICAN DIETETIC ASSOCIATION, 1992, 92 (03) : 293 - &
[36] FDA: Approval of generic drug reversed by US court of appeals
Beliveau, S
JOURNAL OF LAW MEDICINE & ETHICS, 2002, 30 (01): : 120 - 122
[37] Congress Seeks FDA Documents About Generic Drug Approvals
Rubin, Rita
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2016, 315 (06): : 549 - 549
[38] PHARMACEUTICALS FDA offers guidance for updating generic drug labels
Hess, Glenn
CHEMICAL & ENGINEERING NEWS, 2016, 94 (29) : 17 - 17
[39] FDA Critical Path Initiatives: Opportunities for Generic Drug Development
Robert A. Lionberger
The AAPS Journal, 2008, 10 : 103 - 109
[40] FDA critical path initiatives: Opportunities for generic drug development
Lionberger, Robert A.
AAPS JOURNAL, 2008, 10 (01): : 103 - 109

← 1 2 3 4 5 →